CagriSema
Human dataCagrilintide plus semaglutide — the only compound in this class built on amylin rather than a second incretin receptor. Strong Phase 3 numbers, and it lost the one head-to-head trial it ran.
Peptide Index
Every compound this site covers, organized by what it is studied for. The badge on each card states the evidence class honestly: a compound with only rodent data says so. Each guide cites its primary sources, and the research database holds every citation in one filterable list.
Weight & Metabolic
Retatrutide
Human dataGIP/GLP-1/glucagon triple agonist in Phase 3 trials. The strongest human evidence base of any compound covered here, and not yet approved.
Semaglutide
Human dataGLP-1 agonist approved as Wegovy and Ozempic. The deepest evidence base in the class, including cardiovascular outcome data.
Survodutide
Human dataGlucagon/GLP-1 dual agonist (BI 456906). The weakest weight numbers of the new generation — and the strongest liver-disease data, which is arguably its real indication.
Tirzepatide
Human dataGIP/GLP-1 dual agonist approved as Zepbound and Mounjaro — the strongest results of any currently prescribable weight-loss drug.
Repair & Recovery
BPC-157
Animal data onlyGastric pentadecapeptide with an extensive rodent literature on gut, tendon and nerve healing — and no controlled human trial.
BPC-157 + TB-500
Animal data onlyThe blend vial sold as a repair stack. No study has tested the two compounds in combination.
TB-500
Animal data onlySynthetic fragment of thymosin β4. The parent protein reached human trials; the fragment sold as a research chemical has not.
Growth Hormone
CJC-1295
Human dataGHRH analog sold in two forms that behave nothing alike: with DAC a single dose lasts days, without DAC about thirty minutes. Human studies measured hormone levels, never outcomes.
CJC-1295 + Ipamorelin
Human dataGHRH analog plus selective ghrelin agonist. Small human pharmacology studies exist for each compound; no outcome trial of the blend.
MK-677 (Ibutamoren)
Human dataOrally active ghrelin mimetic — not a peptide. Unusually well studied for this catalog: a two-year randomized trial, a failed Alzheimer's trial, and a hip-fracture trial stopped early for a heart-failure signal.
Sermorelin
Human dataGHRH(1-29) — a formerly FDA-approved drug (Geref) for pediatric growth hormone deficiency, discontinued for business reasons. The anti-aging use rests on hormone-level studies, not outcome trials.
Tesamorelin
Human dataThe only GHRH analog with a current FDA approval — Egrifta, for excess abdominal fat in HIV-associated lipodystrophy. Full Phase 3 program, liver-fat and muscle data.
Mitochondrial & Longevity
MOTS-c
Animal data onlyMitochondrially encoded peptide with animal metabolic data; human data is observational only.
SS-31 (Elamipretide)
Human dataCardiolipin-binding mitochondrial peptide: FDA approved as FORZINITY for Barth syndrome in 2025, and separately failed its Phase 3 trial in primary mitochondrial myopathy.
Skin & Cosmetic
GHK-Cu
Mixed evidenceCopper tripeptide with strong in-vitro collagen data, one largely negative randomised human trial of the topical form, and no human data for the injected form.
GLOW (GHK-Cu + BPC-157 + TB-500)
Animal data onlyA pre-mixed three-peptide blend sold for skin and recovery. No study has tested the combination; the evidence for each component is separate and mostly preclinical.
Melanotan II
Human dataNon-selective melanocortin agonist, never approved anywhere. The human evidence is early trials plus a series of published adverse-event case reports.
Sexual Function
PT-141 (Bremelanotide)
Human dataMelanocortin agonist approved as Vyleesi for HSDD in premenopausal women. Full human trial program and an FDA label.
Inflammation & Gut
KPV
Animal data onlyα-MSH C-terminal tripeptide studied in cell and mouse models of intestinal inflammation. Preclinical only.
Adjacent Compounds
5-Amino-1MQ
Animal data onlyNNMT inhibitor — not a peptide. Mouse fat-loss and muscle data; no human trial published or registered.
Dihexa
Animal data onlyAngiotensin IV-derived compound studied for cognition in rodents. The paper behind its famous potency claim was retracted in 2025, and no human trial has ever been published.
AOD-9604
Animal data onlyGH fragment studied for lipolysis in mice; the human phase 2 obesity data exists only in company disclosures. Covered in the fat-loss rankings.
Research use only. Compounds described as research chemicals are not FDA approved for human use. Nothing on this site is medical advice.